Sign In
Buy OCGN
$1.21
-0.0600 (-4.72%)
At Close: Jul 24, 2026
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 20
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
08:02pm, Friday, 10'th Jul 2026
Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigme
Ocugen to Participate in Upcoming July Industry Conferences
07:00am, Wednesday, 01'st Jul 2026
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
12:36pm, Thursday, 04'th Jun 2026
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
12:51pm, Wednesday, 03'rd Jun 2026
OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
12:41pm, Wednesday, 03'rd Jun 2026
Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028
12:36pm, Wednesday, 03'rd Jun 2026
Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.
Ocugen to Participate in Upcoming June Investor and Industry Conferences
07:03am, Tuesday, 02'nd Jun 2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
04:30pm, Thursday, 14'th May 2026
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the clos
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
01:15pm, Wednesday, 13'th May 2026
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
07:02am, Wednesday, 13'th May 2026
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the
Ocugen (OCGN) Upgraded to Buy: Here's Why
01:01pm, Friday, 08'th May 2026
Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
01:05pm, Wednesday, 06'th May 2026
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
02:51pm, Tuesday, 05'th May 2026
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
11:00am, Tuesday, 05'th May 2026
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.
